Rx Cost Management Should Emphasize Generics Over Rebates - BC/BS Exec
Executive Summary
The goal for pharmacy managers should be a decline in drug budgets over the next few years in light of patent expirations, Regence Blue Shield of Idaho Assistant VP-Pharmacy Services Terrance Killilea told the Pharmaceutical Benefit Management Institute April 28 in Scottsdale, Ariz.
You may also be interested in...
PBM Standards Allow Preparation Of Formulary Reviews For P&T Committee
Pharmacy benefit management standards developed by the trade association PCMA allow PBMs to provide an initial formulary review to an independent pharmacy and therapeutics committee.
PBM Standards Allow Preparation Of Formulary Reviews For P&T Committee
Pharmacy benefit management standards developed by the trade association PCMA allow PBMs to provide an initial formulary review to an independent pharmacy and therapeutics committee.
Amgen's Kineret Arthritis Product Being Watched By Medco For Cost Impact
Merck-Medco anticipates FDA approval for Amgen's rheumatoid arthritis treatment Kineret as early as the first quarter of 2001. The PBM is keeping close track of development of the drug as one of a handful of R&D projects that could have a significant impact on drug spending when they reach the market.